What the research found

Researchers tracked appetite-related experiences in nearly 240 people using weekly GLP-1 medications (semaglutide or tirzepatide) by asking them to report daily on "food noise" (intrusive thoughts about food), cravings, hunger, and feeling full. The pattern that emerged was cyclical: immediately after each weekly injection, food noise and hunger dropped significantly, but both gradually climbed back up as the week progressed, nearly returning to post-injection levels by Day 7. Most participants reported at least some cravings over the six-week observation period, though the intensity was typically moderate rather than severe. Fullness and satiety showed less dramatic swings across the weekly cycle.

This is a real-world observational study—participants simply reported their own experiences rather than being assigned to controlled conditions. The daily diary approach captured nuances that traditional clinical visits (typically spaced weeks apart) would miss: the appetite-suppressing effect of these drugs appears to follow a predictable rhythm tied to the injection schedule.

Why it matters for you

If you're using weekly GLP-1 therapy, this data suggests your appetite control is not constant throughout the week. You may experience a "sweet spot" of reduced food noise and hunger in the first 2–3 days after injection, then find cravings creeping back by mid-week. This has practical implications: if you struggle most near the end of your cycle, you might plan your training schedule, meal prep, or social eating events with that rhythm in mind rather than assuming consistent appetite suppression.

The finding about food noise—intrusive food thoughts—is particularly relevant if you track adherence to nutrition protocols. GLP-1 effects on this subjective experience fade before the next dose, so expecting the same mental ease Day 6 as Day 1 could lead to unnecessary frustration. For MyKine users correlating appetite logs with weight, energy, or training performance, this cyclical pattern is worth noting: a day of stronger cravings might reflect your position in the dosing interval rather than a protocol failure.

Conversely, the stability of fullness and satiety signals across the week—they don't swing as wildly as hunger or food noise—suggests that meals feel satisfying even on lower-suppression days, which could be reassuring for adherence.

Caveats

• Self-reported only: all data came from participant recollection and subjective scales; no objective biomarkers of appetite hormones
• US-based convenience sample: may not reflect the experience of users in other healthcare systems or demographic groups
• No control arm: no comparison to people not on GLP-1 therapy, so we cannot isolate the drug effect from other factors
• Short observation window: six weeks may not capture longer-term patterns, tolerance development, or dose adjustments
• Industry context unclear: funding and sponsorship details not stated in the abstract